Table 5.
Multivariate regression using Fine-Gray subdistributional hazards model of calcific uremic arteriolopathy adverse events (safety analysis set)
| Multivariate Model | Hazard Ratio (95% CI) | P Value |
|---|---|---|
| Treatment (cinacalcet versus placebo) | 0.25 (0.10 to 0.67) | <0.01 |
| Male sex (reference, female) | 0.33 (0.14 to 0.75) | <0.01 |
| Body mass index (per kg/m2) | 1.09 (1.05 to 1.13) | <0.001 |
| Diastolic BP (per 10 mmHg) | 1.50 (1.19 to 1.90) | <0.001 |
| History of dyslipidemia | 2.15 (0.90 to 5.15) | 0.09 |
| History of parathyroidectomy | 5.79 (1.79 to 18.70) | 0.003 |
| Baseline tobacco use (reference, never use) | ||
| Current | 1.79 (0.54 to 5.89) | 0.34 |
| Former | 3.04 (1.19 to 7.74) | 0.02 |
Baseline variables were included using backward elimination. Heart failure and diabetes mellitus were removed during the backward elimination procedure at a significance level of 0.10. Additional baseline variables of age, vitamin K antagonist use, vitamin D sterol use, and peripheral vascular disease were evaluated but not included in the multivariate regression model using the backward elimination procedure because they did not meet the entry criteria, P<0.25 in a univariate model. 95% CI, 95% confidence interval.